EGFR and neoplasm: For example, EGFR mutant organoids were sensitive to EGFR inhibitors, while NF1-mutant organoids with disrupted RAS/RAF/MEK signaling presented sensitivity to MEK inhibitors indicated by reduced tumor cell proliferation [15].